Scott Patterson

Scott Patterson, PhD is Vice President of Biomarker Sciences in the R&D organization at Gilead Sciences, Inc., where he is responsible for the development and implementation of biomarker and diagnostic strategies across all the company’s therapeutic areas. Previously, he was Executive Director, Medical Sciences at Amgen, Inc., where he established the company’s biomarker strategy and led the In Vitro Diagnostics Group from its inception. Prior to Amgen, Dr. Patterson was Vice President, Proteomics at Celera Genomics. Earlier in his career, he held research appointments at Amgen and at Cold Spring Harbor Laboratory, New York. Dr. Patterson received BSc and PhD degrees from The University of Queensland in Australia.